A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

October 16, 2017




Bictegravir was also tested in an unusually constructed Phase II trial that pitted coformulated B/F/TAF against multi-pill regimens consisting of emtricitabine/tenofovir alafenamide (Descovy, FTC/TAF) plus either bictegravir or dolutegravir. Paul Sax, M.D., presented the results on Oct. 6.

Ninety-eight treatment-naive people living with HIV were enrolled in the blinded phase of the trial; of those, 65 took bictegravir plus FTC/TAF and 33 took dolutegravir plus FTC/TAF. At week 60, the study was unblinded and all 92 people still in the study switched from the multi-pill regimen to single-pill B/F/TAF. Twelve weeks after the switch, 99% of the participants maintained their HIV-1 RNA

B/F/TAF is being studied in two additional ongoing Phase III trials: a trial studying people who maintained dolutegravir/abacavir/lamivudine treatment compared with switching to B/F/TAF, and another studying people who maintained dolutegravir plus FTC/TAF compared with switching to B/F/TAF.

Image credit: Sylverarts for iStock via Thinkstock.

Related Stories

Top HIV Researcher Hails a Resurgent Antiretroviral Pipeline
Ignorance About PrEP Is Common Among Health Care Providers, Studies Suggest
Long-Acting HIV Treatment: 5 Myths and Realities

This article was provided by It is a part of the publication IDWeek 2017.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.